Value-added data goes beyond basic data as it is not routinely developed or shared, has been transformed or analyzed in a customized way (i.e., aggregated customer data), is delivered more frequently than basic data, is requested and provided on a more ad hoc basis
Pharma determines access, pricing, supply, and exits, the four pillars of GLP-1 market stability.(e.g., Roche, AbbVie, Novo Nordisk) They control the drug pipeline and reimbursement Pharmas licensing, M&A, and distribution decisions determine what products clinicians can prescribe and what insurers will cover
That last detail matters: Foundayo is not cannibalizing injectable patients
609 The ORR of ICBs is relatively lower than targeted therapies, although ICBs provide durable responses